The 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston, uniting industry leaders from the likes of Sanofi, Kite, Ultragenyx, Sangamo, UCB, and more to focus on advancing the production of viral vectors for cell and gene therapeutics.

2024 has been pivotal for viral vector manufacturing, with more gene therapies in market and regulatory frameworks evolving to support scalable production. With 800+ gene therapy candidates in clinical trials, the focus is on optimizing processes to reduce costs and improve consistency.

Don’t miss the only summit dedicated to viral vector process development and manufacturing, featuring talks, panels, roundtables, and 2 interactive workshops. Gain valuable insights into the regulatory landscape and data-driven presentations across upstream and downstream process development on key topics such as:

Elevating Yield, Titer, and Potency

Improving Capsid Ratios

Advancing Purification Techniques

Enhancing Scale-Up

Seamless Tech Transfer

Enhancing Vector Optimization

… and more!

Event link here.